HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Schüler, Susanne ^a   Fritsche, Petra ^a   Diersch, Sandra ^a   Arlt, Alexander ^b   Schmid, Roland M ^a   Saur, Dieter ^a   Schneider, Günter ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; CASPASE 8; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; PROTEIN BID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VALPROIC ACID; ENZYME INHIBITOR; HDAC2 PROTEIN, HUMAN; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA; PROTEIN CLEAVAGE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; BIOSYNTHESIS; DRUG EFFECT; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; ENZYME INHIBITORS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HUMANS; PANCREATIC NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; VALPROIC ACID;

EID: 77950814683     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-80     Document Type: Article

References (53)

1. Schneider G, Siveke JT, Eckel F, Schmid RM. Pancreatic cancer: basic and clinical aspects. Gastroenterology 2005, 128:1606-1625. 10.1053/j.gastro.2005.04.001, 15887154.
2. Mitry E, Rachet B, Quinn MJ, Cooper N, Coleman MP. Survival from cancer of the pancreas in England and Wales up to 2001. Br J Cancer 2008, 99(Suppl 1):S21-23. 10.1038/sj.bjc.6604576, 2557526, 18813249.
3. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960-1966. 10.1200/JCO.2006.07.9525, 17452677.
4. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008, 9:206-218. 10.1038/nrm2346, 2667380, 18292778.
5. Buchwald M, Krämer OH, Heinzel T. HDACi--targets beyond chromatin. Cancer Lett 2009, 280:160-167. 10.1016/j.canlet.2009.02.028, 19342155.
6. Spange S, Wagner T, Heinzel T, Krämer OH. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 2009, 41:185-198. 10.1016/j.biocel.2008.08.027, 18804549.
7. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets?. Cancer Lett 2009, 277:8-21. 10.1016/j.canlet.2008.08.016, 18824292.
8. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007, 26:5420-5432. 10.1038/sj.onc.1210610, 17694083.
9. Schneider G, Krämer OH, Fritsche P, Schüler S, Schmid RM, Saur D. Targeting histone deacetylases in pancreatic ductal adenocarcinoma. J Cell Mol Med 2009,
10. Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 2009, 107:600-8. 10.1002/jcb.22185, 19459166.
11. Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res 2009, 15:3970-3977. 10.1158/1078-0432.CCR-08-2786, 19509171.
12. Richards DA, Boehm KA, Waterhouse DM, Wagener DJ, Krishnamurthi SS, Rosemurgy A, Grove W, Macdonald K, Gulyas S, Clark M, Dasse KD. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann Oncol 2006, 17:1096-1102. 10.1093/annonc/mdl081, 16641168.
13. Fritsche P, Seidler B, Schüler S, Schnieke A, Göttlicher M, Schmid RM, Saur D, Schneider G. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 2009, 58:1399-1409. 10.1136/gut.2009.180711, 19528037.
14. Göttlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. Embo J 2001, 20:6969-6978. 10.1093/emboj/20.24.6969, 125788, 11742974.
15. Krämer OH, Zhu P, Ostendorff HP, Golebiewski M, Tiefenbach J, Peters MA, Brill B, Groner B, Bach I, Heinzel T, Göttlicher M. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. Embo J 2003, 22:3411-3420. 10.1093/emboj/cdg315, 165640, 12840003.
16. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002, 2:277-288. 10.1038/nrc776, 12001989.
17. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-4811. 10.1038/sj.onc.1209608, 16892092.
18. Hamacher R, Schmid RM, Saur D, Schneider G. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer 2008, 7:64. 10.1186/1476-4598-7-64, 2515336, 18652674.
19. Fulda S. Apoptosis pathways and their therapeutic exploitation in pancreatic cancer. J Cell Mol Med 2009, 13:1221-1227. 10.1111/j.1582-4934.2009.00748.x, 19382915.
20. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008, 7:1001-1012. 10.1038/nrd2637, 18989337.
21. Newsom-Davis T, Prieske S, Walczak H. Is TRAIL the holy grail of cancer therapy?. Apoptosis 2009, 14:607-623. 10.1007/s10495-009-0321-2, 19194800.
22. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Balci MK, Omer A, Griffith TS, Sanlioglu S. High levels of endogenous tumor necrosis factor-related apoptosis-inducing ligand expression correlate with increased cell death in human pancreas. Pancreas 2008, 36:385-393. 10.1097/MPA.0b013e318158a4e5, 18437085.
23. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Ozdogan M, Suleymanlar I, Balci MK, Griffith TS, Sanlioglu S. High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients. Pancreas 2009, 38:154-160. 10.1097/MPA.0b013e31818db9e3, 18981952.
24. Ozawa F, Friess H, Kleeff J, Xu ZW, Zimmermann A, Sheikh MS, Büchler MW. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett 2001, 163:71-81. 10.1016/S0304-3835(00)00660-1, 11163110.
25. Koschny R, Walczak H, Ganten TM. The promise of TRAIL--potential and risks of a novel anticancer therapy. J Mol Med 2007, 85:923-935. 10.1007/s00109-007-0194-1, 17437073.
26. Vogler M, Durr K, Jovanovic M, Debatin KM, Fulda S. Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 2007, 26:248-257. 10.1038/sj.onc.1209776, 16832350.
27. Lehmann A, Denkert C, Budczies J, Buckendahl AC, Darb-Esfahani S, Noske A, Muller BM, Bahra M, Neuhaus P, Dietel M, et al. High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer 2009, 9:395. 10.1186/1471-2407-9-395, 2779818, 19912635.
28. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009, 280:168-176. 10.1016/j.canlet.2008.10.047, 19103471.
29. Marchion DC, Bicaku E, Turner JG, Schmitt ML, Morelli DR, Munster PN. HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol Cancer Ther 2009, 8:794-801. 10.1158/1535-7163.MCT-08-0985, 19372552.
30. Bicaku E, Marchion DC, Schmitt ML, Munster PN. Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. Cancer Res 2008, 68:1513-1519. 10.1158/0008-5472.CAN-07-2822, 18316616.
31. Kaler P, Sasazuki T, Shirasawa S, Augenlicht L, Klampfer L. HDAC2 deficiency sensitizes colon cancer cells to TNFalpha-induced apoptosis through inhibition of NF-kappaB activity. Exp Cell Res 2008, 314:1507-1518. 10.1016/j.yexcr.2008.01.010, 18314102.
32. von Burstin J, Eser S, Paul MC, Seidler B, Brandl M, Messer M, von Werder A, Schmidt A, Mages J, Pagel P, et al. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 2009, 137:361-371. 371 e361-365, 10.1053/j.gastro.2009.04.004, 19362090.
33. Krämer OH. HDAC2: a critical factor in health and disease. Trends Pharmacol Sci 2009, 30:647-55. 10.1016/j.tips.2009.09.007, 19892411.
34. Bai J, Sui J, Demirjian A, Vollmer CM, Marasco W, Callery MP. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res 2005, 65:2344-2352. 10.1158/0008-5472.CAN-04-3502, 15781649.
35. Retzer-Lidl M, Schmid RM, Schneider G. Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin. Int J Cancer 2007, 121:66-75. 10.1002/ijc.22619, 17304504.
36. Song JJ, An JY, Kwon YT, Lee YJ. Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance. Involvement of Bcl-xL. J Biol Chem 2007, 282:319-328. 10.1074/jbc.M608065200, 17110373.
37. Wang P, Zhang J, Bellail A, Jiang W, Hugh J, Kneteman NM, Hao C. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal 2007, 19:2237-2246. 10.1016/j.cellsig.2007.06.001, 17693058.
38. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Gschwend JE, Simmet T, Debatin KM, Fulda S. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res 2008, 68:7956-7965. 10.1158/0008-5472.CAN-08-1296, 18829553.
39. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Bhanot U, Hasel C, Moller P, Gschwend JE, et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 2009, 69:2425-2434. 10.1158/0008-5472.CAN-08-2436, 19258513.
40. Mori T, Doi R, Kida A, Nagai K, Kami K, Ito D, Toyoda E, Kawaguchi Y, Uemoto S. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells. J Surg Res 2007, 142:281-286. 10.1016/j.jss.2007.03.068, 17640673.
41. Huang S, Sinicrope FA. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res 2008, 68:2944-2951. 10.1158/0008-5472.CAN-07-2508, 18413764.
42. Huang S, Okumura K, Sinicrope FA. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin Cancer Res 2009, 15:150-159. 10.1158/1078-0432.CCR-08-1575, 19118042.
43. Murtaza I, Saleem M, Adhami VM, Hafeez BB, Mukhtar H. Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells. Cancer Res 2009, 69:1156-1165. 10.1158/0008-5472.CAN-08-2917, 19176377.
44. Natoni F, Diolordi L, Santoni C, Gilardini Montani MS. Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways. Biochim Biophys Acta 2005, 1745:318-329. 10.1016/j.bbamcr.2005.07.003, 16109447.
45. Braeuer SJ, Buneker C, Mohr A, Zwacka RM. Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol Cancer Res 2006, 4:715-728. 10.1158/1541-7786.MCR-05-0231, 17050666.
46. Trauzold A, Wermann H, Arlt A, Schutze S, Schafer H, Oestern S, Roder C, Ungefroren H, Lampe E, Heinrich M, et al. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene 2001, 20:4258-4269. 10.1038/sj.onc.1204559, 11464292.
47. Khanbolooki S, Nawrocki ST, Arumugam T, Andtbacka R, Pino MS, Kurzrock R, Logsdon CD, Abbruzzese JL, McConkey DJ. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther 2006, 5:2251-2260. 10.1158/1535-7163.MCT-06-0075, 16985059.
48. Fulda S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr Cancer Drug Targets 2008, 8:132-140. 10.2174/156800908783769355, 18336196.
49. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008, 269:7-17. 10.1016/j.canlet.2008.03.037, 18462867.
50. Inoue S, Twiddy D, Dyer MJ, Cohen GM. Upregulation of TRAIL-R2 is not involved in HDACi mediated sensitization to TRAIL-induced apoptosis. Cell Death Differ 2006, 13:2160-2162. 10.1038/sj.cdd.4401977, 16729023.
51. Inoue S, Harper N, Walewska R, Dyer MJ, Cohen GM. Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis. Mol Cancer Ther 2009, 8:3088-3097. 10.1158/1535-7163.MCT-09-0451, 19887558.
52. Reichert M, Saur D, Hamacher R, Schmid RM, Schneider G. Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. Cancer Res 2007, 67:4149-4156. 10.1158/0008-5472.CAN-06-4484, 17483325.
53. Schneider G, Henrich A, Greiner G, Wolf V, Lovas A, Wieczorek M, Wagner T, Reichardt S, von Werder A, Schmid RM, et al. Cross talk between stimulated NF-kappaB and the tumor suppressor p53. Oncogene 2010,